Ireland to get 300 Regeneron jobs in $300m manufacturing boostSome 300 pharmaceutical manufacturing jobs are to be created over three years in Limerick, Ireland, by Regeneron, the Share XIreland to get 300 Regeneron jobs in $300m manufacturing boosthttps://pharmaphorum.com/news/ireland-to-get-300-regeneron-jobs-in-300m-manufacturing-boost/
Valeant buys cosmetic surgery devices company for $250 millionValeant Pharmaceuticals is seeking to strengthen its cosmetics business with an agreement to buy Solta Medical for about Share XValeant buys cosmetic surgery devices company for $250 millionhttps://pharmaphorum.com/news/valeant-buys-cosmetic-surgery-devices-company-for-250-million/
Tunnah’s musings: Collaborative healthcare gains ground with #G8dementia summitAs 2013 draws to a close, Paul Tunnah muses on the fact that there is increasing recognition that Share XTunnah’s musings: Collaborative healthcare gains ground with #G8dementia summithttps://pharmaphorum.com/views-and-analysis/tunnah-s-musings-collaborative-healthcare-gains-ground-with-g8dementia-summit/
GlaxoSmithKline to spend a billion raising its stake in IndiaGlaxoSmithKline is to pay £629 million (64 billion Indian rupee and about one billion US dollars) in raising Share XGlaxoSmithKline to spend a billion raising its stake in Indiahttps://pharmaphorum.com/news/glaxosmithkline-to-spend-a-billion-raising-its-stake-in-india/
‘Low but stable’ pharma growth in 2014The ratings agency Fitch has said in its 2014 outlook report for global branded pharmaceuticals that it forecasts Share X‘Low but stable’ pharma growth in 2014https://pharmaphorum.com/news/low-but-stable-pharma-growth-in-2014/
First-in-class diabetes drug recommended for FDA approvalAstraZeneca and Bristol-Myers Squibb have received a positive opinion from an FDA committee for dapagliflozin, a sodium-glucose cotransporter Share XFirst-in-class diabetes drug recommended for FDA approvalhttps://pharmaphorum.com/news/first-in-class-diabetes-drug-recommended-for-fda-approval/
Female sexual dysfunction company to keep fighting for its pillHaving taken on the development of flibanserin from Boehringer Ingelheim and put the drug for a problem with Share XFemale sexual dysfunction company to keep fighting for its pillhttps://pharmaphorum.com/news/female-sexual-dysfunction-company-to-keep-fighting-for-its-pill/
Cognitive effects of antidepressant buoy LundbeckLundbeck has risen to a two-year high on the markets after announcing the cognitive results of a trial Share XCognitive effects of antidepressant buoy Lundbeckhttps://pharmaphorum.com/news/cognitive-effects-of-antidepressant-buoy-lundbeck/
J&J nestles into five UK ‘excellence’ citiesJohnson & Johnson is continuing to establish a scientific networking approach with the establishment of five new partnerships Share XJ&J nestles into five UK ‘excellence’ citieshttps://pharmaphorum.com/news/j-j-nestles-into-five-uk-excellence-cities/
